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Abstract Based on the 7-year experience of the Italian
Clinical Network for FSHD, we revised the FSHD clinical
form to describe, in a harmonized manner, the phenotypic
spectrum observed in FSHD. The new Comprehensive
Clinical Evaluation Form (CCEF) defines various clinical
categories by the combination of different features. The
inter-rater reproducibility of the CCEF was assessed
between two examiners using kappa statistics by evaluating
56 subjects carrying the molecular marker used for FSHD
diagnosis. The CCEF classifies: (1) subjects presenting
facial and scapular girdle muscle weakness typical of
FSHD (category A, subcategories A1–A3), (2) subjects
with muscle weakness limited to scapular girdle or facial
muscles (category B subcategories B1, B2), (3) asymp-
tomatic/healthy subjects (category C, subcategories C1,
C2), (4) subjects with myopathic phenotype presenting
clinical features not consistent with FSHD canonical phe-
notype (D, subcategories D1, D2). The inter-rater relia-
bility study showed an excellent concordance of the final
four CCEF categories with a j equal to 0.90; 95 % CI
(0.71; 0.97). Absolute agreement was observed for cate-
L. Ruggiero and L. Vercelli contributed equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s00415-016-8123-2) contains supplementary
material, which is available to authorized users.
& Rossella Tupler
rossella.tupler@unimore.it
1 Department of Life Sciences, University of Modena and
Reggio Emilia, Modena, Italy
2 Department of Clinical and Experimental
Medicine, Neurological Clinic, University of Pisa,
Pisa, Italy
3 Department of Neurosciences, Reproductive and
Odontostomatological Sciences, University Federico II of
Naples, Naples, Italy
4 Department of Neuroscience, Center for Neuromuscular
Diseases, University of Turin, Turin, Italy
5 MRC Centre of Epidemiology for Child Health, UCL
Institute of Child Health, London, UK
6 IRCCS San Camillo, Venice, Italy
7 Department of Neuroscience, Mental Health and Sensory
Organs, S. Andrea Hospital, University of Rome ‘‘Sapienza’’,
Rome, Italy
8 Unit of Child Neurology and Psychiatry, IRCCS ‘‘C.
Mondino’’ Foundation, Pavia, Italy
9 Department of Neurosciences, University of Padua, Padua,
Italy
10 Center for Neuromuscular Disease, CeSI, University ‘‘G.
D’Annunzio’’, Chieti, Italy
11 Department of Neurorehabilitation, IRCCS Institute Eugenio
Medea, Bosisio Parini, Italy
12 Neurology Clinic, ‘‘Spedali Civili’’ Hospital, Brescia, Italy
13 IRCCS Foundation, C. Besta Neurological Institute, Milan,
Italy
14 Neuromuscular Unit, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Dino Ferrari Center,
University of Milan, Milan, Italy
15 Department of Clinical and Experimental Medicine,
University of Messina, Messina, Italy
16 Department of Neurological, Neuropsychological,
Morphological and Movement Sciences, University of
Verona, Verona, Italy
17 Department of Molecular Cell and Cancer Biology,
University of Massachusetts Medical School, Worcester,
USA
123
J Neurol (2016) 263:1204–1214
DOI 10.1007/s00415-016-8123-2
gories C and D, an excellent agreement for categories A
[j = 0.88; 95 % CI (0.75; 1.00)], and a good agreement
for categories B [j = 0.79; 95 % CI (0.57; 1.00)]. The
CCEF supports the harmonized phenotypic classification of
patients and families. The categories outlined by the CCEF
may assist diagnosis, genetic counseling and natural history
studies. Furthermore, the CCEF categories could support
selection of patients in randomized clinical trials. This
precise categorization might also promote the search of
genetic factor(s) contributing to the phenotypic spectrum of
disease.
Keywords FSHD  Clinical phenotype  Diagnostic
criteria  Disease registry  Disease classification
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is one of
the most common forms of hereditary myopathy [1]. The
classical FSHD phenotype is rather distinctive, character-
ized by a progressive asymmetric facial, shoulder girdle
and pectoral muscle weakness and atrophy, with a
descending progression to involve the distal lower
extremity muscles before affecting the hip girdle muscles
[2]. However, a wide variability of clinical expression has
been extensively documented [3].
At present, two genetically distinct disease subtypes,
FSHD1 and FSHD2 are described. The molecular defect
associated with FSHD1 resides in a stretch of tandemly
arrayed 3.3 kb repetitive elements, named D4Z4, ranging
from 11 to 150 repeat units in healthy subjects [4]. Alleles
with 8 or fewer D4Z4 repeats on chromosome 4q have
been found in the majority of FSHD patients. FSHD2
patients carry D4Z4 alleles of size at the lower end of the
general healthy population range size [5]. In these patients,
the disease is associated with heterozygous dominant
mutations in the SMCHD1 gene [6].
However, D4Z4 alleles in the size-range of FSHD1
patients (4–8 units, 20–35 kb EcoRI alleles) are carried by
3 % of healthy control population [7–9]. Thus, a D4Z4
allele of reduced size may be permissive but it is not suf-
ficient to develop autosomal dominant disease. Consis-
tently, in FSHD families, we found that almost 25 % of
FSHD heterozygotes older than 55 years were asymp-
tomatic [10]. Moreover, there are families in which the
disease appears only in one generation or in a single subject
[8, 10] with no other relatives with signs of disease.
Besides, several reports describe atypical phenotypes in
carriers of a D4Z4 reduced allele (DRA) [11].
Collectively, the extensive use of DNA analysis in
FSHD has revealed an unanticipated complexity without
a straightforward correlation between the clinical
phenotype and molecular variations. Incomplete pene-
trance and wide clinical variability argue for the role of
modifying loci or epigenetic mechanisms influencing the
clinical expression of disease. This clinical and genetic
variability, which is observed also in other hereditary
neuromuscular diseases, represents an obstacle for the
interpretation of clinical data, for genotype-phenotype
correlations, appropriate genetic counseling and for the
definition of a minimal dataset necessary for the strati-
fication of patients eligible for therapeutic trials.
Therefore, to formulate optimal diagnostic criteria,
molecular analysis must be associated with standardized
and harmonized clinical evaluation.
Here, in light of our 7-year experience, we present the
FSHD Comprehensive Clinical Evaluation Form (CCEF), a
modified version of the original FSHD Clinical Form [12]
for the detailed description of all phenotypic features
detected in FSHD patients and families.
Methods
Study design
Through the systematic use of the FSHD Clinical Form
[10, 12, 13] we recognized that it assesses the severity of
motor impairment by translating disability into a number
(FSHD Evaluation Scale, CCEF Section 2, Supplementary
Figure 1), but it does not capture clinical features that may
describe various phenotypes. To overcome this limitation,
we integrated several items including typical and atypical
features on the basis of published reports describing the
clinical phenotypes observed in carriers of a DRA (re-
viewed in [11]). Typical and atypical clinical features were
combined in the new CCEF, which includes the Evaluation
Form (CCEF Section 1, Supplementary Figure 1), the
FSHD Evaluation Scale (CCEF Section 2, Supplementary
Figure 1), the Clinical Diagnostic Form (CCEF Section 3,
Fig. 1), and the Clinical Categories (CCEF Section 4,
Fig. 2). The integral CCEF can be downloaded as Sup-
plementary Figure 1 and at http://www.fshd.it. The defi-
nition and the validation of the CCEF were performed in
two steps. We first recruited 106 subjects carrying a DRA
with 1–9 units (11–38 kb) to test the clinical application of
this new tool. The recruitment was based on 452 subjects
examined by the Italian Clinical Network for FSHD
(ICNF) in 2-year time-window (2008–2009). Subjects were
summoned by consecutive phone calls following the order
of the previous recruitment. We called those near the
clinical centers of Modena, Turin and Naples. The latter
choice was made to avoid people a long-distance trip. We
organized three meetings dividing the 106 available sub-
jects into three groups on the basis of their geographic
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location (Northern, Central and Southern Italy). Twelve
experienced clinicians of the ICNF were selected according
to their geographic location, so that four neurologists
examined patients from each one of the three groups. The
four selected neurologists used the CCEF to evaluate each
subject of a single group independently. The results of this
Fig. 1 CCEF Section 3: Clinical Diagnostic Form
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first round of clinical applications were discussed in a
subsequent meeting. We revised the emerged critical
points, i.e. some difficulties in establishing mild facial
weakness, and approved the final version of the CCEF
(Supplementary Figure 1). Then, in a second round, the
inter-rater reliability in assigning patients to different
phenotypic categories using the new CCEF was tested.
Two clinicians, selected by drawing lots, examined
CATEGORY A
Category A1
Severe facial weakness (unable both to close eyes and to protrude lips) + impairment of 
upper limb abduction with winged scapula (scapular FSHD score 1) + absence of 
uncommon features
Category A2
Facial weakness (upper and lower facial weakness) + impairment of upper limb abduction 
with winged scapula (scapular FSHD score 1) + absence of uncommon features
Category A3
Facial weakness (upper or lower facial weakness) + impairment of upper limb abduction with 
winged scapula (scapular FSHD score 1) + absence of uncommon features
CATEGORY B
Category B1
Impairment of upper limb abduction with winged scapula (scapular FSHD score 1), no facial 
weakness + absence of uncommon features
Category B2
Facial weakness (facial FSHD score 1), no impairment of upper limb abduction + absence of 
uncommon features
CATEGORY C
Category C1
Subject with presence of at least one typical sign + FSHD score =0
Category C2
Subject without signs of muscle weakness + FSHD score =0
CATEGORY D
Category D1
Subject fulfilling criteria of categories A1, A2, A3, B1, B2 + at least one uncommon feature
Category D2
-Subject fulfilling criteria of categories C1 or C2 + at least one uncommon feature
-Subject no fulfilling criteria of any of the above categories
Fig. 2 CCEF Section 4: Clinical Categories
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additional 56 subjects (Supplementary Table 1) recruited
from the cohort of 452 subjects as described above. The
two clinicians administered the functional motor evaluation
test of the Evaluation Form (Supplementary Figure 1,
Section 1, parts b and c) to each subject and calculated the
FSHD clinical score on the basis of the FSHD Evaluation
Scale, previously validated [12]. Then, the two clinicians
completed the Clinical Diagnostic Form (CCEF Section 3,
Fig. 1) and assigned each subjects to one of the nine
clinical subcategories (CCEF Section 4, Fig. 2) indepen-
dently. A tutorial for the clinical assessment is available at
http://www.fshd.it. It takes 20 min to collect clinical
information and complete the neurologic evaluation.
The subject recruitment was approved by the Ethics
Committee of Modena and all the participating centers.
Signed informed consent from patients was obtained before
inclusion in the study.
Statistical analysis
The inter-observer reproducibility between the two exam-
iners respect to the four and nine CCEF categories was
assessed using the kappa statistics [14]. j value scores are
interpreted as follows: j value 1.0 = perfect agreement; j
value C0.75\ 1.0 = excellent; j value [0.40\ 0.75
= good; j value B0.40 = poor. The 95 % confidence
intervals of kappa statistics were calculated using the (bi-
ased corrected) bootstrap resampling method [15].
Results
A tool to describe clinical variability
The CCEF consists of four sections. The first section, the
Evaluation Form (Section 1, Supplementary Figure 1),
investigates the subject’s clinical history (part a), evaluates
the patient’s disability (part b) and assesses muscle seg-
mental involvement using the Medical Research Council
(MRC) scale (part c). The other sections include the FSHD
Evaluation Scale (Section 2, Supplementary Figure 1), the
Clinical Diagnostic Form (Section 3, Fig. 1) and the
Clinical Categories (Section 4, Fig. 2).
Several items are examined in the Evaluation Form
section.
Family history
Questions such as ‘‘did/does any of your relatives have a
posture like yours?’’, ‘‘was any of your relatives sleeping
with half-open eyes?’’ are asked to identify subjects with
possible muscle weakness suggestive of FSHD.
Evaluation of age at onset
To obtain a more objective evaluation of age at onset and
the type of muscle initially affected, we introduced specific
questions, such as ‘‘have your relatives ever noticed that
you were sleeping with half-open eyes?’’, ‘‘when have you
noticed the appearance of winged scapula?’’, ‘‘have you
ever noticed thinness of upper arms or a dropped shoul-
der?’’, ‘‘have you ever noticed asymmetry of the mouth or
smile when looking in a mirror or in past photographs from
childhood?’’.
Functional motor evaluation
For a precise description of the distribution of muscle
weakness, the CCEF evaluates: (a) the presence of widened
palpebral fissures; orbicular oris weakness, horizontal
smile; inability to protrude lips, to puff out cheeks, to close
eyes and bury the eyelashes (facial weakness); (b) the
maximum degree in abducting arms (scapular girdle
weakness); (c) the ability to climb 4 stair-steps, to stand up
from a chair, to rise from the floor, to walk (pelvic girdle
weakness); (d) the ability to walk on tiptoes and/or heels
(distal legs weakness); (e) the presence of Beevor’s sign
(abdominal muscles weakness).
Evaluation of segmental muscle strength by MRC scale
Fourteen muscle groups are examined. Neck extensors are
evaluated as single muscle group; external-rotator muscles
of upper limb, triceps, biceps, common finger extensors,
wrist extensors, long fingers flexors, wrist flexors, gluteus
maximum, iliopsoas, quadriceps, biceps femoris, triceps
surae, tibialis anterior are evaluated on both sides.
Annotation of typical signs
Shoulders with symmetric/asymmetric winging on
attempted shoulder abduction or forward flexion, straight
clavicles, forward sloping of shoulders at rest, axillary
creases reflecting pectoral muscle wasting, sunken or flat-
tened appearance of the chest, ‘‘poly-hill sign’’ with neck,
shoulders and arms observed from behind in fullest pos-
sible abduction (70–90), with external rotation of the
shoulders, hyperlordosis.
Annotation of atypical signs
Palpebral ptosis [2], myotonic phenomenon [16], muscle
rippling [17], weakness of extra-ocular [2], masticatory,
pharyngeal and lingual muscles [2, 18], bent spine syn-
drome [19], early contractures [2], pes cavus [20], dropped
1208 J Neurol (2016) 263:1204–1214
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head, myoglobinuria and persistently high CK values
above the level of 1000 U/L are [2] considered atypical
signs. The presence of cardiomyopathy and a respiratory
restrictive insufficiency at onset or in subjects still walking
(FSHD score\12) is also considered an atypical sign [2,
21].
The Evaluation Form allows completing the FSHD
Evaluation Scale to calculate the FSHD clinical score
(Section 2, Supplementary Figure 1) [12]. The score con-
siders the regional distribution of muscle weakness and the
functionality of: (I) facial muscles (scored from 0 to 2); (II)
scapular girdle muscles (scored from 0 to 3); (III) upper
limb muscles (scored from 0 to 2); (IV) leg muscles (scored
from 0 to 2); (V) pelvic girdle muscles (scored from 0 to 5);
and (VI) abdominal muscles (scored from 0 to 1). Overall,
the total FSHD score ranges from 0 to 15 and numerically
defines the clinical severity of the motor impairment [10,
12, 13].
All sections of CCEF are used for the assessment and
the classification of a patient. Based on the distribution of
muscle weakness, scored by the FSHD Evaluation Scale,
and the combination of the clinical features suggestive or
not of FSHD, summarized in the Clinical Diagnostic Form
(CCEF Section 3, Fig. 1), it is possible to assign patients to
different phenotypic categories (CCEF Section 4, Fig. 2).
In particular, we assigned (1) subjects with typical FSHD
presenting facial and scapular girdle muscle weakness in
category A; (2) subjects with muscle weakness limited to
facial or scapular girdle muscles in category B; (3)
asymptomatic subjects without motor impairment in
category C; (4) subjects with myopathic phenotype pre-
senting other anomalous clinical features not consistent
with FSHD in category D.
Moreover, in view of our experience on FSHD pheno-
types accrued through the past years in INRF [10, 13], we
further described additional variants within each category
(Fig. 2). Patients with typical phenotype were classified in
three subcategories (A1–A3), on the basis of the severity of
facial involvement, which seems to discriminate some
classical phenotypes (Fig. 3a–c). This is because, we
observed that some infantile forms or more severe pheno-
types [13] are characterized by an early and prominent
weakness of orbicularis oculi and oris with facial diplegia
and dysartria. Thus, these patients were defined as category
A1 to distinguish them from the vast majority of patients in
which we observed a milder facial involvement (categories
A2 and A3). This distinction should facilitate the identifi-
cation of a specific clinical group deserving ad hoc studies.
Incomplete FSHD phenotype, not presenting a coexist-
ing involvement of facial and scapular girdle muscles
without other uncommon features, are considered category
B1 or B2 (Fig. 3d, e). We identified these categories
because, for instance, an isolated scapular girdle muscle
weakness can be observed in FSHD relatives, but it can be
also related to other myopathic disorders or nerve injuries.
Category D comprises myopathic subjects presenting
some FSHD features in association with other uncommon
characteristics suggestive of a possible comorbidity (D1) or
patients that do not fulfill the diagnostic criteria for FSHD
and can be affected by an alternative disease (D2) (Fig. 3h,
i). Atypical features were chosen based on evidences from
the literature [11]. This category may facilitate the dis-
covery of factors that contribute to the disease expression
or identify those subjects who are wrongly considered
FSHD because of a diagnostic bias due to the random
finding of DRA.
Finally, we decided to further differentiate non penetrant
carriers: the asymptomatic subjects without motor impair-
ment that present minor signs suggestive of FSHD (‘‘typ-
ical features-other signs’’ Fig. 1) are described as category
C1, whereas category C2 includes subjects with a neuro-
logic examination completely normal (Fig. 3f, g). This
distinction might be of particular importance for studying
the natural history of disease (i.e. subjects described as C1
might develop clinical FSHD later or remain
asymptomatic).
Overall, the categories we generated aim at describing
different phenotypes thus capturing clinical diversity,
regardless of the severity of motor impairment, otherwise
reported as FSHD score.
bFig. 3 Examples of clinical categories: case reports. a Category A1:
male, 38-year old, showing severe upper and lower facial weakness
(unable to close both eyelids completely, puff cheeks and protrude
lips), and impairment of upper limb abduction with winged scapula.
b Category A2: female, 31-year old, with moderate upper (partial
ability to close eyes, without the presence of widened palpebral
fissures) and lower facial weakness (partial ability to puff out cheeks),
impairment of upper limb abduction with winged scapula. c Category
A3: male, 60-year old, with moderate lower facial weakness (partial
ability to protrude lips), impairment of upper limb abduction with
winged scapula. d Category B1: male, 66-year old, with impairment
of upper limb abduction with winged scapula, no facial weakness.
e Category B2: female, 34-year old, with moderate lower facial
weakness (partial ability to puff out cheeks and to protrude lips), no
scapular weakness. f Category C1: female, 55-year old, presenting
asymmetric scapular winging on forward flexion without motor
impairment (FSHD score 0). g Category C2: male, 56-year old,
without motor impairment or other FSHD typical signs of muscle
atrophy/weakness (FSHD score 0). h Category D1: male, 66-year old:
onset after 50 age at shoulder girdle, without facial motor impairment
and ‘‘bent spine’’. i Category D2: male, 75-year old, with isolated bent
spine syndrome, without signs suggestive of FSHD
1210 J Neurol (2016) 263:1204–1214
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Inter-rater reliability of phenotype subgroups
The characteristics of the 56 FSHD patients enrolled in the
inter-rater reliability study are shown in Supplementary
Table 1. The sample is almost balanced by sex, 34 % aged
less than 40 years, 12.5 % had an FSHD score higher than
10, all but three carried a DRA with 8 or fewer repeats
(p13E-11 EcoRI fragments B35 kb).
The concordance between the clinical assessments per-
formed by the two neurologists was evaluated for the nine
CCEF categories described in Fig. 2. As shown in Table 1,
a good/excellent agreement [j = 0.75; 95 % CI (0.57;
0.87)] was observed using the nine CCEF classifications.
The overall kappa statistic combines the reliability of the
nine categories with a perfect agreement observed for
categories B2, C2, D1, D2; a good/excellent agreement for
categories A1, A2, B1 and C2, and a good agreement
observed for the category A3. The results of the concor-
dance of the final four CCEF categories are presented in
Table 2. As expected, the reliability increased with a j
equal to 0.90; 95 % CI (0.71; 0.97). A perfect agreement
was observed for categories C and D, an excellent agree-
ment for categories A [j = 0.88; 95 % CI (0.75; 1.00)],
and a good agreement for categories B [j = 0.79; 95 % CI
(0.57; 1.00)]. A lower level of j, when compared with
values obtained for each subcategory, is due to the
increased number of categories taken into account in the
final score and reflects the sensitivity of the test.
Discussion
The recently published Guidelines on FSHD of the
American Academy of Neurology [22] represent an
attempt toward the formulation of optimal standards of
diagnosis and care for patients. In these recent Guidelines
on FSHD, a relevant diagnostic significance is attributed to
the detection of D4Z4 alleles associated with the 4qA
polymorphism regardless of the phenotypic features.
However, large-scale genotype-phenotype studies have
revealed incomplete penetrance and wide variable expres-
sivity in FSHD [8–11, 23] supporting the role of modifying
loci or epigenetic mechanisms influencing the clinical
expression of disease [5, 6]. Moreover, the FSHD molec-
ular signature has a frequency of 1.3 % [7], which
decreases the specificity of the molecular testing for FSHD.
So, in our opinion, diagnosis of FSHD must be supported
by the harmonized description of the observed clinical
phenotypes and the family history.
Nowadays, studies suggest the role of epigenetic mod-
ifiers in FSHD onset and expression, including the level of
4q35 methylation and/or mutations in SMCHD1 gene [5,
24]. Besides, a vast number of reports describe subjects
with peculiar/atypical phenotypes carrying a DRA and
suggest that mutations in other genes, i.e. gene associated
with other neuromuscular diseases, might contribute to
disease phenotype [11]. This genetic heterogeneity requires
the harmonized classification of clinical phenotypes among
patients and within families to serve clinical practice. In
FSHD, intra-familial clinical variability is one of the most
relevant challenges affecting clinical practice and genetic
Table 1 Agreement between
Observer 1 and Observer 2 with
respect to the nine CCEF
categories classification
CCEF categories Observer 2
A1 A2 A3 B1 B2 C1 C2 D1 D2 Total
Observer 1 A1 6 2 0 0 0 0 0 0 0 8
A2 1 18 2 0 0 0 0 0 0 21
A3 0 2 4 2 0 0 0 0 0 8
B1 0 0 1 5 0 0 0 0 0 6
B2 0 0 0 0 2 0 0 0 0 2
C1 0 0 0 0 0 2 0 0 0 2
C2 0 0 0 0 0 1 4 0 0 5
D1 0 0 0 0 0 0 0 2 0 2
D2 0 0 0 0 0 0 0 0 2 2
Total 7 22 7 7 2 3 4 2 2 56
j = 0.75; 95 % CI (0.57; 0.87)
Table 2 Agreement between Observer 1 and Observer 2 with respect
to the fourth CCEF categories classification
CCEF categories Observer 2
A B C D Total
Observer 1 A 35 2 0 0 37
B 1 7 0 0 8
C 0 0 7 0 7
D 0 0 0 4 4
Total 36 9 7 4 56
j = 0.90; 95 % CI (0.71; 0.97)
J Neurol (2016) 263:1204–1214 1211
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Fig. 4 Clinical characterization of families in which a DRA segregates. Five families are presented. For each subject carrying a 4qA-type DRA
on a permissive haplotype, age at evaluation, size of the DRA, clinical category and FSHD score are reported
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counseling. Our work shows that the CCEF is an easy
clinical tool useful to capture various phenotypes from
classic FSHD to individuals with incomplete phenotype, or
asymptomatic carriers as well as subjects with atypical
signs for which alternative diagnoses may be supposed.
The choice of the nine categories responds to the necessity
of describing the wide clinical spectrum of FSHD patients
and their relatives with a simple and direct approach.
Notably, the CCEF collects several items regarding
anamnestic data, including onset, disease progression,
distribution and degree of motor impairment (measured as
the FSHD Evaluation Scale).
By applying the CCEF, it will be possible to quickly
classify families on the basis of the harmonized
description of genotypes and phenotypes. This classifi-
cation will support genetic counseling taking into
account disease penetrance and expression within a
single family. Figure 4 shows some examples. Figure 4a
displays a family with the canonical autosomal dominant
pattern of inheritance. The disease is present in all three
generations and all subjects, carrying a DRA, display
facial and scapular girdle weakness typical of FSHD,
categories A2 and A3. Figure 4b shows a family in
which two sibs are severely affected (A1) whereas the
father carrying the same 3U DRA (no somatic mosai-
cism of the DRA was detected) is healthy (C2). Fig-
ure 4c presents a four-generation pedigree in which a
single 29-year-old subject, III.2, developed mild weak-
ness of orbicularis oris and weakness of scapular girdle
muscle (category A3). She carries a 6U DRA inherited
by her healthy 55-year-old father, II.2 (category C2).
The paternal 37-year-old aunt, carrying the 6U DRA, is
asymptomatic with non-specific signs as horizontal
clavicles and axillary creases (category C1) and the
paternal 72-year-old grandmother, I.2, carrying the 6U
DRA, presents only incomplete and mild weakness of
facial muscle (category B2). Figure 4d describes a
family with a single patient presenting severe myopathy
with atypical phenotype (D2). The 63-year-old proband
carries a DRA with 9 units as do the twin brother and
the 70-year-old sister, both healthy (C2). Finally, Fig. 4e
displays a family that may mimic an autosomal domi-
nant inheritance. The proband (II.5), carrying a DRA,
presents a typical FSHD phenotype (A3). His mother
(I.2) carries the same DRA, but she displays an atypical
phenotype (D1) without the facial muscle involvement,
and with an early and predominant involvement of the
pelvic girdle probably related to old age. Instead, his two
older sisters (II.1 and II.2) are asymptomatic carriers. In
our opinion, all these unexpected distribution of clinical
phenotypes require particular attention in evaluating the
risk of disease onset and expression, and the possible
contribution of genetic modifiers. Indeed, the systematic
application of the CCEF might support physicians in the
identification of these critical families that might be
suitable for further investigations and promote the
understanding of disease pathophysiology.
Moreover, using the CCEF, it is possible to obtain the
longitudinal trajectory of disease progression for each
patient and describe the disease’s natural history, including
the follow-up of non-manifesting carriers.
Overall, the CCEF is a flexible tool that can assist
novel strategies to study the etiology of rare diseases. It
can support a catalog of the phenotypes observed among
and within families facilitating the phenotypic stratifi-
cation of FSHD patients, the search of genetic modifiers,
and studies on the natural history of disease. Finally, the
harmonized clinical classification of subjects is funda-
mental for the stratification of patients eligible for clin-
ical trials. In this perspective, the CCEF can be an
instrument for observational studies or randomized
clinical trials.
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